These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 32870563)
21. The Enzyme-Free Release of Nucleotides from Phosphoramidates Depends Strongly on the Amino Acid. Jovanovic D; Tremmel P; Pallan PS; Egli M; Richert C Angew Chem Int Ed Engl; 2020 Nov; 59(45):20154-20160. PubMed ID: 32757352 [TBL] [Abstract][Full Text] [Related]
22. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study. Wakchaure PD; Ghosh S; Ganguly B J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493 [TBL] [Abstract][Full Text] [Related]
23. Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate. Xie Y; Hu T; Zhang Y; Wei D; Zheng W; Zhu F; Tian G; Aisa HA; Shen J J Org Chem; 2021 Apr; 86(7):5065-5072. PubMed ID: 33733767 [TBL] [Abstract][Full Text] [Related]
24. Synthesis of Remdesivir Derivate as a Generation of Anti-COVID-19 Drugs Through Acetylation Reactions. Sumardi R; Rifai Y; Alam G Arch Razi Inst; 2023 Dec; 78(6):1753-1761. PubMed ID: 38828177 [TBL] [Abstract][Full Text] [Related]
25. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19. Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898 [No Abstract] [Full Text] [Related]
26. Remdesivir as a broad-spectrum antiviral drug against COVID-19. Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946 [TBL] [Abstract][Full Text] [Related]
27. A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir. Gadzińska J; Kuchar E; Matysiak M; Wanke-Rytt M; Kloc M; Kubiak JZ J Pediatr Hematol Oncol; 2022 Mar; 44(2):e537-e538. PubMed ID: 33885040 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of Remdesivir for COVID-19. Zhang H; Chen J; Wang X; Chen B Discov Med; 2021; 31(163):57-60. PubMed ID: 34965372 [TBL] [Abstract][Full Text] [Related]
29. Checkmahomed L; Carbonneau J; Du Pont V; Riola NC; Perry JK; Li J; Paré B; Simpson SM; Smith MA; Porter DP; Boivin G Antimicrob Agents Chemother; 2022 Jul; 66(7):e0019822. PubMed ID: 35708323 [No Abstract] [Full Text] [Related]
30. Structure-aided ACEI-capped remdesivir-loaded novel PLGA nanoparticles: toward a computational simulation design for anti-SARS-CoV-2 therapy. Wu J; Wang H; Li B Phys Chem Chem Phys; 2020 Dec; 22(48):28434-28439. PubMed ID: 33305304 [TBL] [Abstract][Full Text] [Related]
31. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516 [No Abstract] [Full Text] [Related]
32. Remdesivir for patients with COVID-19. Wu PE; Morris AM CMAJ; 2021 Jan; 193(4):E125. PubMed ID: 33408097 [No Abstract] [Full Text] [Related]
33. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457 [TBL] [Abstract][Full Text] [Related]
34. Remdesivir: a pendulum in a pandemic. Schwartz IS; Heil EL; McCreary EK BMJ; 2020 Nov; 371():m4560. PubMed ID: 33234523 [No Abstract] [Full Text] [Related]
35. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit. Sun D AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279 [TBL] [Abstract][Full Text] [Related]
36. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients. Odeti S; Yellepeddi VK Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893 [No Abstract] [Full Text] [Related]
37. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type. Mohammad A; Al-Mulla F; Wei DQ; Abubaker J Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274 [TBL] [Abstract][Full Text] [Related]
38. 1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication. Zhang L; Zhang D; Wang X; Yuan C; Li Y; Jia X; Gao X; Yen HL; Cheung PP; Huang X Phys Chem Chem Phys; 2021 Mar; 23(10):5852-5863. PubMed ID: 33688867 [TBL] [Abstract][Full Text] [Related]
39. Genomic diversity and molecular dynamics interaction on mutational variances among RB domains of SARS-CoV-2 interplay drug inactivation. Uddin MB; Sajib EH; Hoque SF; Bappy MNI; Elahi F; Ghosh A; Muhit S; Hassan MM; Hasan M; Chelliah R; Park SJ; Mony TJ; Oh DH; Ahmed SSU Infect Genet Evol; 2022 Jan; 97():105128. PubMed ID: 34752930 [TBL] [Abstract][Full Text] [Related]
40. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19. Chua KP; Conti RM JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]